A Single Center, Phase 2B, Randomized, Double Blind, Study to Assess the Efficacy, Safety, and Tolerability of ALLOD-2 vs. Placebo in the Prevention of Episodic Migraine in Adults (ANODYNE-3)
Phase of Trial: Phase II/III
Latest Information Update: 08 Sep 2017
At a glance
- Drugs ALLOD 2 (Primary)
- Indications Migraine with aura; Migraine without aura
- Focus Therapeutic Use
- Acronyms ANODYNE-3
- Sponsors Allodynic Therapeutics
- 04 Aug 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Aug 2018.
- 04 Aug 2017 Status changed from not yet recruiting to recruiting.
- 11 Jul 2017 Planned End Date changed from 12 Oct 2018 to 17 Oct 2018.